This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;68(11):2435-44.
doi: 10.1093/jac/dkt221. Epub 2013 Jun 20.

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal

Affiliations
Review

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal

Angela Loyse et al. J Antimicrob Chemother. 2013 Nov.

Abstract

Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice. However, access to flucytosine in Africa and Asia, where disease burden is greatest, is inadequate at present. While research into identifying effective and well-tolerated antifungal combinations that do not contain flucytosine continues, an ever-increasing body of evidence from in vitro, in vivo and clinical studies points to the benefits of flucytosine in the treatment of CM in both intravenous combinations with amphotericin B and oral combinations with high-dose fluconazole. This article provides an up-to-date review of this evidence, and the current issues and challenges regarding increasing access to this key component of combination antifungal therapy for cryptococcosis.

Keywords: 5-FC; 5-FC safety; access to essential antifungals for cryptococcal meningitis; combination antifungal therapy; cryptococcal meningitis; cryptococcal meningitis treatment guidelines; opportunistic infection.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Intracellular pathway and mode of action of 5-fluorouracil (5-FU). Adapted with permission from Vermes et al. 5-FU is converted into 5-fluorouridine triphosphate (FUTP). FUTP alters the aminoacylation of tRNA through its incorporation into fungal RNA in place of uridylic acid, causing RNA miscoding and disturbed synthesis of proteins and carbohydrates. In addition, 5-FU is metabolized to 5-fluorodeoxyuridine monophosphate (FdUMP). FdUMP is a potent inhibitor of thymidylate synthetase, a key enzyme in the biosynthesis of DNA.
Figure 2.
Figure 2.
Survival curves, by treatment group, for patients with HIV-associated cryptococcal meningitis in Vietnam treated with AmB (1 mg/kg/day) (Arm I) alone for 4 weeks (continuous line), with 5-FC (100 mg/kg/day) (Arm II) for 2 weeks (black dashed line) or with fluconazole (800 mg/day for 2 weeks) (grey dotted/dashed line), followed by fluconazole in all three arms. HR (95% CI) at 14/7, II versus I: 0.57 (0.30, 1.08), P = 0.08; III versus I: 0.71 (0.45, 1.11), P = 0.13; at 70/7, II versus I: 0.61 (0.39, 0.97), P = 0.04; III versus I: −0.78 (0.44, 1.41), P = 0.42. From Day JN, Tran TTH, Wolbers M et al. N Engl J Med 2013;368: 1291–302. Copyright Massachusetts Medical Society 2013. Reprinted with permission.
Figure 3.
Figure 3.
Survival curves, by treatment group for patients with HIV-associated cryptococcal meningitis in Malawi treated with fluconazole 1200 mg/day or fluconazole 1200 mg/day plus flucytosine 100 mg/kg/day for the initial 2 weeks. One patient lost to follow up was censored. P = 0.05 at 2 weeks and P = 0.25 at 10 weeks by Cox regression. Reproduced with permission from Day et al.

References

    1. Duchinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropyrimidines. J Am Chem Soc. 1957;79:4559–60.
    1. Heidelberger C, Griesbach L, Montag B, et al. Studies on fluorinated pyrimidines. Effects on transplanted tumours. Cancer Res. 1958;18:305–17. - PubMed
    1. Grunberg E, Titsworth E, Bennett M. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother. 1963:566–8. - PubMed
    1. Tassel D, Madoff MA. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA. 1968;206:830–2. - PubMed
    1. Block ER, Bennett JE. Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother. 1972;1:476–82. - PMC - PubMed

Publication types

MeSH terms

Full text links
Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /